- Coromandel’s net income for the third quarter was 5.12 billion rupees, significantly higher than the previous year’s 2.31 billion rupees and above the estimated 4.24 billion rupees.
- Revenue increased by 27% year-over-year to 69.35 billion rupees, surpassing the expected 62.56 billion rupees.
- Total costs rose by 22% year-over-year to 63.57 billion rupees.
- Raw material costs decreased by 6.4% year-over-year to 33.6 billion rupees, which was significantly lower than the estimated 49.16 billion rupees.
- A dividend of 6 rupees per share was declared.
- Analyst recommendations include 8 buy ratings, 1 hold, and 2 sell positions.
A look at Coromandel International Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 3 | |
| Growth | 3 | |
| Resilience | 5 | |
| Momentum | 5 | |
| OVERALL SMART SCORE | 3.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Coromandel International Ltd., a company specializing in the manufacturing of fertilizers and pesticides, has received positive Smartkarma Smart Scores across various factors. With a solid Resilience score of 5 and Momentum score of 5, the company demonstrates stability and strong upward momentum in its operations. This indicates that Coromandel International has shown resilience in challenging times and continues to grow at a steady pace.
Looking ahead, the overall outlook for Coromandel International appears favorable based on its Smartkarma Smart Scores. While the company’s Value, Dividend, and Growth scores are all at a moderate 3, the high scores in Resilience and Momentum suggest a promising long-term trajectory for the company. Investors may find Coromandel International a potentially rewarding investment option in the foreseeable future.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
